Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02042430Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epacadostat in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoint: Number of participants with an increase in CD8+ T cells. Started Aug 2014; status: completed.
02
Drugs
epacadostat
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02042430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042430.